PUBLIC RELEASE DATE:

17-Mar-2014

Contact: Megan Hanks mhanks@acponline.org 215-351-2656 American College of Physicians

1. Evidence does not support guidelines on fatty acid consumption to reduce coronary risk

Current evidence does not support nutritional guidelines that advocate high consumption of polyunsaturated fatty acids and low consumption of total saturated fats, according to an article being published in Annals of Internal Medicine. For cardiovascular health, nutritional guidelines generally encourage low consumption of saturated fats, high consumption of w-3 polyunsaturated fatty acids, and avoidance of trans fats. However, uncertainties in available evidence have contributed to the considerable variation in international guidelines about optimum amounts and types of fatty acids people should consume. Further complicating data interpretation, earlier analyses have generally not assessed the consistency between studies that rely on dietary self-report and biomarker measures of fatty acids in relation to coronary disease. Researchers conducted a systematic review and meta-analysis of data from long-term prospective observational studies of a broad range of both dietary and biomarker fatty acid measures in coronary disease. They also examined associations with coronary outcomes in randomized trials of fatty acid supplementation. The researchers' findings did not support cardiovascular guidelines that promote high consumption of long-chain w-3 and w-6 polyunsaturated fatty acids and reduced consumption of total saturated fatty acids. They also found that supplementation did not statistically significantly reduce the risk for coronary outcomes.

Note: The URL will go live at 5:00 p.m. on Monday, March 17 and can be included in news stories. For an embargoed PDF, please contact Megan Hanks or Angela Collom. The lead author, Dr. Rajiv Chowdhury, may be contacted directly at RC436@medschl.cam.ac.uk.

2. Patients co-infected with HIV and HCV more likely to suffer liver decompensation

Despite treatment with antiretroviral therapy (ART), patients co-infected with HIV and hepatitis C virus (HCV) have higher rates of liver decompensation than patients with HCV alone, according to an article being published in Annals of Internal Medicine. Up to 30 percent of patients with HIV also are often co-infected with HCV and HCV-related liver complications are an important cause of morbidity in co-infected patients. It has been suggested that ART slows HCV-associated liver fibrosis. However, whether rates of hepatic decompensation and other severe liver events in co-infected patients receiving ART are similar to those with HCV only remains unclear. Veterans Affairs researchers compared health records for 4,280 patients co-infected with HIV and HCV who initiated ART with those of 6,079 veterans with HCV only to compare hepatic decompensation rates. Co-infected patients that had HIV RNA levels less than 1,000 copies/ML had a lower rate of hepatic decompensation than those with a lesser degree of HIV suppression. However, the rate was still higher than that of patients with HCV alone. Higher rates of decompensation were seen in co-infected patients receiving ART who had baseline advanced liver fibrosis, severe anemia, diabetes, and were of nonblack race.

Note: The URL will go live at 5:00 p.m. on Monday, March 17 and can be included in news stories. For an embargoed PDF, please contact Megan Hanks or Angela Collom. To interview the lead author, please contact Steve Graff at Stephen.Graff@uphs.upenn.edu or 215-349-5653.

3. Pneumonia coding practices may skew hospital performance outcomes

Here is the original post:

Annals of Internal Medicine tip sheet for March 18, 2014